['hiv infection']
['abx464', 'placebo']

        Inclusion Criteria:

          -  Patients infected with HIV;

          -  Patients with HIV plasma viral load ≤ 50 copies mL-1 during the 6 months prior to
             screening with a maximum of 2 blips during this period;

          -  Patients treated by DRV/RTV or DRV/COBI as a monotherapy for at least 8 weeks prior to
             baseline;

          -  Patients' HIV plasma viral load ≤100,000 copies mL-1 at any time (apart from primary
             infection if recorded);

          -  Patients' CD4+ T cells count ≥ 250 cells per mm3 at any time since diagnosis;

          -  Patients with CD4+ T cells count ≥ 600 cells per mm3 at screening;

          -  Man or woman aged 18-65 years;

        Exclusion Criteria:

          -  Patient displaying any HIV protease inhibitor resistance mutation as listed in the
             current version of the HIV drug resistance database (Stanford University);

          -  Patient having had previously a viral load ≥ 500 copies mL-1 confirmed by a second
             measure since the initiation of the current ART;

          -  History of an AIDS-defining clinical illness;

          -  Concomitant AIDS-related opportunistic infection;
      